An international, multicenter, epidemiological, observational study investigating the prevalence of Hereditary Angioedema (HAE) disease among participants with recurrent episodes of abdominal pain of no obvious etiology.
Hereditary Angioedema (HAE) is a rare autosomal dominant disorder characterized most commonly by deficient (type 1) or nonfunctional (type 2) C1 inhibitor protein (encoded by SERPING1 gene). The disorder is associated with episodes of angioedema of the face, larynx, lips, abdomen, and extremities. The angioedema is caused by the activation of the kallikrein-kinin system that leads to the release of vasoactive peptides, followed by edema, which in severe cases can be life threatening. Gastrointestinal involvement occurs in 93% of patients with HAE and may be the only manifestation of the disease. However, individuals with gastrointestinal symptoms are rarely considered for HAE and the disease can be misdiagnosed for several years. EHA study focuses on the gastrointestinal complications of HAE as a potential area of misdiagnosis leading to surgical morbidity. Aim of the study is to investigate the prevalence of HAE among participants experiencing recurrent abdominal pain attacks with no clear etiology. The HAE-positive samples in the study will be further analyzed biochemically to identify disease-specific biomarker that may support the development of new diagnostic tools for HAE disease.
Study Type
OBSERVATIONAL
Enrollment
2,318
Epidemiological analysis of prevalence of the HAE in participants with previous episodes of abdominal pain of no obvious etiology.
Dry Blood Spot (DBS)-based biochemical measurements of C4 complement and the protease C1 inhibitor levels will be analyzed via liquid chromatography multiple reaction. The pathological biochemical results will be genetically validated via combination of the Next-Generation Sequencing (the mutation will be confirmed by Sanger sequencing) and Multiplex ligation-dependent probe amplification of SERPING1.
Time frame: 4 years
Establishment of a biomarker in HAE-positive cohort
HAE-positive samples will be analyzed for the identification of potential biomarkers (based on MS/MS-Tandem spectroscopy) and compared with the merged control samples in order establish a HAE specific biomarker.
Time frame: 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Praxis und Tagesklinik Prof. Dr. med. Jens Papke
Neustadt, Saxony, Germany
Universitätsklinikum Düsseldorf, Klinik für Allgemein-, Viszeral- und Kinderchirurgie
Düsseldorf, Germany
Dr. med. Engelhard | Dr. med. Wihl, Internistische Gemeinschaftspraxis
Frankenberg, Germany
Universitätsmedizin Greifswald Körperschaft des öffentlichen Rechts
Greifswald, Germany
Klinikum Kassel GmbH
Kassel, Germany
Universitätsklinikum Leipzig AöR
Leipzig, Germany
Johannes Wesling Klinikum Minden, Universitätsklinik der Ruhr Universität Bochum
Minden, Germany
Kinder- und Jugendklinik, Universitätsmedizin Rostock
Rostock, Germany
Azienda Ospedaliera Antonio Cardarelli
Napoli, Italy
Hiroshima University Graduate School of Biomedical Sciences
Hiroshima, Japan
...and 25 more locations